<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984954</url>
  </required_header>
  <id_info>
    <org_study_id>HMPE202001</org_study_id>
    <nct_id>NCT04984954</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Shexiang Baoxin Pill on Coronary Microvascular Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Hutchison Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Hutchison Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective to evaluate the effect of Shexiang Baoxin Pill on myocardial ischemia in patients&#xD;
      with coronary microvascular dysfunction (non obstructive coronary heart disease) through a&#xD;
      randomized, double-blind, placebo-controlled clinical multicenter study.At the same time, the&#xD;
      effects of exercise tolerance and quality of life were also observed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 stratified block random grouping according to the center</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the difference of HRR between the experimental group and the placebo group was significant</measure>
    <time_frame>At the end of treatment (8 weeks (± 1 week))</time_frame>
    <description>Definition of abnormal heart rate recovery: peak HR during exercise - HR one minute into recovery at the end of exercise is defined as abnormal heart rate recovery when HR one minute into recovery is less than 12 beats / min.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Angina Pectoris</condition>
  <condition>Coronary Heart Disease</condition>
  <condition>X Syndrome, Angina</condition>
  <condition>Non Obstructive Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group was given placebo 4 capsules / day, 3 times / day, until the end of follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MUSK pill</intervention_name>
    <description>This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up</description>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18-80, male or female;&#xD;
&#xD;
          2. Selective coronary angiography or coronary CTA showed that the diameter of coronary&#xD;
             artery ≥ 2.5mm, the degree of stenosis &lt; 50%, without myocardial bridge;&#xD;
&#xD;
          3. They were able to perform treadmill exercise, and the treadmill test (EET) was&#xD;
             positive;&#xD;
&#xD;
          4. Angina pectoris was found;&#xD;
&#xD;
          5. Patients are willing to follow up and sign informed consent; All the above criteria&#xD;
             should be met.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Coronary heart disease complicated with hypertrophic cardiomyopathy;&#xD;
&#xD;
          2. There was a history of AMI, PCI and CABG, and myocardial bridge was found by&#xD;
             angiography or CTA;&#xD;
&#xD;
          3. Patients with severe medical diseases (liver, kidney, hematopoietic system and other&#xD;
             serious primary diseases, etc.);&#xD;
&#xD;
          4. Mental disorders and mental diseases;&#xD;
&#xD;
          5. Patients with pulmonary failure and NYHA heart function grade III-IV, unable to carry&#xD;
             out exercise test;&#xD;
&#xD;
          6. Contraindications of Shexiang Baoxin Pill: forbidden for pregnant women;&#xD;
&#xD;
          7. Those who have known history of allergy to Shexiang Baoxin Pills;&#xD;
&#xD;
          8. Recently, the patient has taken Shexiang Baoxin Pill and other anti ischemic&#xD;
             traditional Chinese medicine regularly, or it contains borneol, toad venom and other&#xD;
             ingredients in Shexiang Baoxin Pill;&#xD;
&#xD;
          9. Combined with frequent ventricular premature beats, ventricular tachycardia, atrial&#xD;
             fibrillation, sinoatrial block, atrioventricular pathway block, left bundle branch&#xD;
             block and right bundle branch block, which may affect the judgment of exercise ECG&#xD;
             results;&#xD;
&#xD;
         10. Researchers think that there are other factors that are not suitable to participate in&#xD;
             the trial; If one of the exclusion criteria is met, it can be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HaiMing Shi, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HaiMing Shi, doctor</last_name>
    <phone>+8613901824859</phone>
    <email>13901824859@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ying Shan, doctor</last_name>
    <phone>+8613402021699</phone>
    <email>shanyingli@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huashan Hospital Fudan University</name>
      <address>
        <city>ShangHai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiming Shi, doctor</last_name>
      <phone>+8613801731588</phone>
      <email>13901824859@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Ying Shan, doctor</last_name>
      <phone>+8613402021699</phone>
      <email>shanyingli@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 4, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Shexiang Baoxin Pill</keyword>
  <keyword>Musk pill</keyword>
  <keyword>Patients with coronary microvascular dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Microvascular Angina</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

